Teva Pharmaceuticals

🍏 🍹 Naši tradiční zdravou snídani jsme v pražské kanceláři tentokrát oživili interaktivní přednáškou! Generální manažer Teva Pharmaceuticals ČR a SR Michael Schrewe nám připomněl pět základních Teva leadership principů, které uplatňujeme v praxi, a poté jsme měli možnost sledovat diskusi kolegů k tomuto tématu. 🙋♂️ Setkání u zdravého jídla doprovázené živou diskusí nám dobře nastartovalo den. 👍 V podobném duchu plánujeme pokračovat každý měsíc – každá zdravá snídaně v Tevě bude mít svoje zajímavé téma! #Teva #TevaCesko #TevaCZ #TevaPharm #Zdravi #ZdravaStrava

Imagine being unable to smile for a family photo because your facial muscles won’t cooperate. Or having your feet twitch so hard they wear holes in your socks or sneakers. This is not unusual for people like Bethany Chalmers, who live with tardive dyskinesia (TD) – a rare movement disorder that can impact a person’s daily life in many big and small ways. And TD is just one of 7,000+ rare diseases affecting millions of people globally. Rare diseases often have no cure, and too often, those living with one of these diseases may feel hopeless and forgotten. This is why research matters. Medical and pharmaceutical breakthroughs have the potential to provide hope and may lead to meaningful change to patients' and their loved ones' lives. To mark Rare Disease Day, let’s stand with those living with rare diseases and work to raise awareness, improve diagnosis and enable access to treatments. Read Bethany's story about three ways in which TD impacts her daily life: https://ow.ly/msh350V69lN #RareDiseaseDay #TardiveDyskinesia #Tevapharm

I am incredibly proud to announce that Teva Pharma ANZ has officially achieved the Great Place to Work certification from the globally recognised GPTW Institute, a milestone we reached in January 2025. This certification reflects the strength of the inclusive and equitable culture we have built together and showcases our commitment to making Teva ANZ a workplace where every employee feels valued, supported, and empowered to succeed.

At Teva Pharma ANZ, our success is rooted in creating an environment where all employees can thrive and perform at their best. We understand that a positive workplace experience goes beyond our actions—it’s about how we ensure all employees are seen and heard. Our approach to People & Culture is key to shaping the culture that propels us forward.

I want to take a moment to express my gratitude to all our ANZ employees for their unwavering dedication and commitment. You are the heart of what makes Teva Pharma ANZ a Great Place to Work. Together, let’s continue striving for even greater accomplishments.

#WeAreAllInForBetterHealth! Stephen Jenkins Mariam Qayum Olive Taylor Juliette Dollimore Koray Koksal Gary McCaw Ben Hall Liliana Chavez chakameh khashayar Ravinder Dhar Inna (Inderpreet) Arora Sinead Forbes Adina Fargher Rebecca Hill Stephanie Chua Olive Taylor Mark Sabag

We are pleased to share that today the FDA has accepted our supplemental New Drug Application for a potential expansion of the indication of our schizophrenia treatment long-acting injectable (LAI) antipsychotic to also include bipolar I disorder. If approved, a new LAI treatment option for those living with #BP1 may help support patients and their HCPs. Read more on this and our continued commitment to advancing care for patients here: https://bit.ly/419IfTw #TevaPharm

Our team is on the ground at the 20th Congress of the European Crohn’s and Colitis Organisation (ECCO) to share the latest on our anti-TL1A program. In December, together with Sanofi, we announced positive topline results for our potentially best-in-class option for moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD), the two most common forms of inflammatory bowel disease, or #IBD. At #ECCO2025, we are looking forward to presenting the latest research with the global IBD community. To read more about our data presented at ECCO, visit: https://ow.ly/QQom50V4JQZ #TevaPharm #PivotToGrowth

Understanding how patients and healthcare professionals use medical devices like insulin pens and asthma inhalers is crucial. However, this has traditionally come late in the design process. Teva is now changing this, by focusing on user needs from the very beginning. “Using engineering analysis, we can anticipate the way a product will perform before we've even manufactured it,” says Paul Bridges, VP Head of Global Combination Products and Device R&D. Discover more about the innovative processes and the teams working to support patients who use these products every day: https://ow.ly/K6mK50UTWOW #Tevapharm

Access to innovative medicines remains a critical issue for patients and at Teva we are tackling this challenge on multiple fronts. Chris Fox, EVP of U.S. Commercial, spoke with STAT on how we’re operating across the full spectrum of innovation — from innovative therapies to essential generics and biosimilars — to better health worldwide. Learn more: https://ow.ly/V9IB50UZyNJ #TevaUSA #WeAreAllInForBetterHealth

Say hi to Nakato. Three years ago, when she was just two years old, Nakato was diagnosed with a tumor after her mother noticed a mass in her stomach. Through the Global HOPE program, she received life-saving treatment, including chemotherapy and surgery. Now, Nakato is in remission. Did you know 4 in 5 children worldwide lack access to the cancer treatments they need? On International Childhood Cancer Day, we honor the strength of children like Nakato and underscore our commitment to improving those odds by training healthcare workers and providing critical medicines. To learn more about how Teva is partnering with Global HOPE: https://ow.ly/AjRp50UZZGx #AccessToMedicines #TevaStories #Tevapharm

Navigating love and relationships with schizophrenia can be a challenge for both parties. As Joanna, whose husband Paweł was diagnosed with schizophrenia after a psychotic episode three years into their relationship, shares: “I didn't understand what was happening, but this version of Paweł seemed worlds away from the content, confident man I'd known and loved for three years.” Joanna and Paweł’s path, marked by initial shocks and the need for a robust support system, highlights how love and patience can lead to a deeper connection. “I also knew Paweł was different in a way that had nothing to do with his disease. He was special.” Read Joanna and Paweł’s story here: https://ow.ly/sWYN50UYsF3 #Tevapharm #Schizophrenia #LifeEffects

“When I got here, everybody said Teva is a generics company. I said, I don’t think it is. When I looked under the hood, I saw this innovation - some launched, some in the pipeline - and then I saw this world-class generics business. I said, this is a pharma company that does both.” Our CEO, Richard Francis, sat down with Pharmaceutical Executive for the publication’s February issue to share his insights on Teva’s progress across the four key pillars of our Pivot to Growth strategy and the significant advancements Teva made in 2024. Richard emphasizes our organization’s commitment to innovation and sustainable growth, sharing a roadmap on where our organization is heading in 2025 and beyond. Check out the full interview from Pharma Exec here: https://ow.ly/BGkz50UZi2c #Tevapharm #PivottoGrowth #Innovation